Selective estrogen receptor downregulators (SERDs)  

Fulvestrant      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

advanced breast cancer (metastatic)

fulvestrant
GEICAM/2006-10fulvestrant + anastrozoleanastrozole HER-2 negative HR positive postmenopausal NCT00543127Risk of bias -
FACT (Bergh), 2012fulvestrant + anastrozoleanastrozole first line of endocrine therapy HR positive postmenopausal NCT00256698negative
Mehta(SWOG-S0226), 2012fulvestrant + anastrozoleanastrozole HR positive NCT00075764suggesting
CDR0000349337 ongoing fulvestrant + anastrozoleanastrozole first line of endocrine therapy postmenopausal NCT00075764Risk of bias ongoing
Xu et al., 2011fulvestrant 250mganastrozole HR positive postmenopausal NCT00327769Low risk of bias -
0021 (Osborne), 2002fulvestrant 250mganastrozole postmenopausal NCT00635713Low risk of bias negative
0020 (Howell), 2002fulvestrant 250mganastrozoleRisk of bias negative
A011106 ongoing fulvestrant 250mganastrozoleNCT01953588Risk of bias ongoing
FIRST (Robertson), 2010fulvestrant 500mganastrozole first line of endocrine therapy postmenopausal NCT00274469suggesting
FALCON ongoing fulvestrant 500mganastrozole first line of endocrine therapy NCT01602380Low risk of bias ongoing
FUMANCE ongoing fulvestrant 500mgcontrol maintenance therapy postmenopausal NCT02383030Risk of bias ongoing
9238UK/0005 (fluvestrant alone)fluvestrant 250mgexemestane postmenopausal previously treated with endocrine therapy NCT00944918Low risk of bias -
SoFEa (Johnston) fluvestrant alone, 2012fluvestrant 250mgexemestane postmenopausal previously treated with endocrine therapy NCT00253422 -
9238UK/0005 (combination)fulvestrant + anastrozoleexemestane postmenopausal previously treated with endocrine therapy NCT00944918Low risk of bias -
SoFEa (Johnston) combination, 2012fulvestrant + anastrozoleexemestane HR positive postmenopausal previously treated with endocrine therapy NCT00253422negative
EFECT (Chia)fulvestrant 250mgexemestane HR positive postmenopausal NCT00065325Low risk of bias negative
D6997L00021fulvestrant 500mgfulvestrant 250mg HR positive previously treated with endocrine therapy NCT01300351Low risk of bias -
CONFIRM (Di Leo), 2010fulvestrant 500mgfulvestrant 250mg HR positive previously treated with endocrine therapy NCT00099437Low risk of bias -
FINDER 1 (Ohno), 2010fulvestrant 500mgfulvestrant 250mg postmenopausal -
FINDER 2, 2010fulvestrant 500mgfulvestrant 250mg postmenopausal previously treated with endocrine therapy NCT00313170Exploratory -
9238IL/0025fulvestrant 250mgtamoxifen first line of endocrine therapy NCT00241449Low risk of bias -
0025 (Howell), 2004fulvestrant 250mgtamoxifen previously treated with endocrine therapy Low risk of bias negative